Sai Parenterals Q1 FY27: Revenue at ₹182 Crore as Company Advances Injectable, R&D and Australia Expansion Plans
Sai Parenterals Limited discussed its Q1 FY27 performance and strategic expansion plans during its earnings conference call held on August 12, 2026. The company highlighted improving margins, its ₹750 crore FY27 revenue target, expansion of injectable manufacturing capacity, the proposed acquisition of stakes in two pharmaceutical assets, and progress at its Australian facility.
Sai Parenterals Q1 FY27 Financial Performance
Sai Parenterals reported consolidated revenue of ₹182 crore in Q1 FY27. The company reported gross profit of ₹76 crore, translating into a gross margin of 41.8%.
Consolidated EBITDA stood at ₹27 crore, with an EBITDA margin of 14.9%, compared with 14.4% in Q4 FY26. Profit after tax stood at ₹8 crore, with a PAT margin of 4.3%.
The company cautioned that year-on-year comparisons are not directly comparable because Noumed Pharmaceuticals was consolidated from November 12, 2025, meaning Q1 FY26 did not include Noumed’s contribution.
Standalone business shows strong growth
On a standalone basis, Sai Parenterals recorded revenue of ₹56 crore, compared with ₹20 crore in Q1 FY26, representing growth of 175%.
Gross profit increased to ₹22 crore from ₹10 crore, while EBITDA rose to approximately ₹17 crore from ₹4 crore. EBITDA margin improved to around 29%, compared with 20% in the year-ago quarter.
Standalone PAT reached ₹9 crore, compared with ₹0.8 crore in Q1 FY26.
FY27 Revenue Guidance Remains at ₹750 Crore
Management maintained its FY27 guidance of ₹750 crore revenue with an EBITDA margin of around 17%.
The company expects the second half of FY27 to contribute more strongly, with management indicating that the business is seasonally weighted toward the second half.
The company said Q1 FY27 represented approximately 24% of its full-year revenue target and was ahead of the required pace based on its expected first-half/second-half revenue split.
Management also indicated that the company remains confident about achieving the ₹750 crore revenue target and approximately 17% EBITDA margin.
Gross Margin Improves Despite Supply Chain Challenges
One of the key positives during the quarter was the improvement in gross margin.
Consolidated gross margin increased to 41.8% from 38.1% in Q4 FY26, an improvement of 370 basis points.
Management attributed part of the improvement to the gradual recovery of higher raw-material costs through contractual price revisions. The company’s contracts typically have a 90–120-day lag between a price revision being notified and the revised pricing being realized.
However, the company also faced higher logistics costs during the quarter. Disruptions in West Asia delayed shipments from India’s contract manufacturing network to Australia. To protect customer commitments, Noumed moved certain inventory by air rather than sea, resulting in elevated freight costs.
Management expects these supply-chain pressures to ease going forward.
₹101.85 Crore IPO Fund Reallocation for Strategic Assets
A major development discussed during the earnings call was the proposed change in the utilization of IPO proceeds.
The Board has proposed redeploying:
- ₹83.83 crore originally allocated for manufacturing capacity expansion and upgradation
- ₹18.02 crore originally earmarked for a new R&D centre
The combined amount of ₹101.85 crore is proposed to be redirected toward investments in two pharmaceutical assets.
The proposed changes are subject to shareholder approval.
Management emphasized that the underlying objective remains unchanged: building European GMP-compliant injectable capacity and strengthening the company’s R&D capabilities. The change is primarily in the execution strategy.
60% Stake Proposed in Saicriti Pharma
Sai Parenterals proposes to acquire a 60% stake in Saicriti Pharma Private Limited for ₹83.83 crore.
Saicriti is developing a critical-care injectable manufacturing facility at Gummadidala, outside Hyderabad’s Outer Ring Road.
The proposed facility is being developed on a site of more than 15,000 square yards, compared with the company’s existing Jeedimetla facility of approximately 3,100 square yards.
According to management, the new facility will be developed to meet European GMP and USFDA standards and will include capabilities for:
- Complex injectables
- Lyophilisation
- GLP
- General injectable manufacturing
- Critical-care products
The proposed facility is expected to provide approximately 154.66 million units of injectable capacity, compared with around 105 million units under the earlier upgradation plan.
That represents approximately 47% higher capacity while the company’s proposed contribution remains ₹83.83 crore.
The facility is targeted for completion around April 2027.
Existing Domestic Business Could Support New Facility
An additional benefit highlighted by management is Saicriti’s existing domestic critical-care business.
The business currently generates approximately ₹52–53 crore of annual domestic sales, with products manufactured through third-party contract manufacturing facilities.
Once the new manufacturing facility becomes operational, these products are expected to be manufactured at the new site.
Management believes this could provide operating leverage and improve utilization of the new facility.
R&D Expansion Through Prathyak Laboratories
Sai Parenterals also proposes to acquire a 60% stake in Prathyak Laboratories Private Limited for ₹15 crore.
Prathyak operates an established pharmaceutical R&D centre at Genome Valley, Hyderabad.
The company has approximately:
- 150 SKUs
- 86 molecules
- 67 personnel
- Around 28 research scientists
- Capabilities in complex injectables
- Lyophilised products
- Liposomal products
- Nano-based injectables
- Oncology injectables
Management said the acquisition provides an established R&D platform rather than requiring Sai Parenterals to build a new research centre from scratch.
The transaction is expected to be completed on or before September 30, 2026, subject to the necessary approvals.
Australia Expansion Remains a Key Growth Driver
Noumed Pharmaceuticals is another important component of Sai Parenterals’ growth strategy.
The Australian business currently operates as an IP registration holder and provides an integrated pharmaceutical platform covering product development, regulatory approvals, inventory management, logistics, warehousing, distribution and regulatory support.
Noumed currently has:
- 5 exclusive long-term contracts
- 10 exclusive supply molecule contracts
- Approximately 526 SKUs
The company has long-term relationships with major Australian pharmacy and healthcare groups.
₹1,300 Crore Australian Contract
One of the most significant developments discussed was the renewed exclusive OTC supply agreement with EBOS Group, covering the TerryWhite Chemmart and Pharmacy Choice networks.
The agreement, renewed effective July 1, 2026, is valued at approximately AUD 202 million, equivalent to around ₹1,300 crore based on the exchange rate cited during the call.
The agreement has an initial tenure of 7.5 years, with an additional potential three-year extension by mutual agreement.
The contract represents approximately AUD 27 million of annual value and includes plans for the addition of 12 new products each year.
Importantly, management clarified that the new product launches are expected to be over and above the existing contract value.
Australia Manufacturing Facility on Track
The company’s Australian manufacturing facility in Adelaide remains on schedule.
Management said physical completion is targeted for January 2027, followed by validation activities and a TGA licensing inspection expected by March 2027.
Phase 1 manufacturing is expected to begin from April 2027.
The facility is expected to manufacture products including:
- Tablets
- Liquid oral formulations
- Nasal sprays
- Creams
- Ointments
The company also expects local manufacturing to reduce its inventory requirements.
At present, Noumed needs to maintain approximately 9–10 months of inventory because of long shipping lead times. Local manufacturing could potentially bring this down to approximately 5–6 months.
Management also expects vertical integration to improve supply reliability and working-capital efficiency.
US Market Entry Under Evaluation
Sai Parenterals has received Board approval to establish a US subsidiary through its Singapore subsidiary.
However, management stressed that the US initiative is currently at a preliminary evaluation stage.
The company is assessing opportunities for entering the US market and has not yet finalized its commercial or manufacturing strategy.
Therefore, the US subsidiary should currently be viewed as an initial platform for evaluating opportunities rather than an immediate revenue contributor.
Debt and Balance Sheet Position
As of June 30, 2026, consolidated debt stood at approximately ₹310 crore, compared with around ₹319 crore at the end of March 2026.
Cash and cash equivalents stood at approximately ₹184 crore.
Management expects FY27 to be a peak year for debt growth as the company completes its ongoing capital expenditure and acquisition program.
From FY28, the company expects deleveraging as the new assets begin contributing to earnings and cash flows.
Management indicated that the gross debt-to-equity ratio is expected to remain around 0.6 times, even at peak debt levels, although additional project debt could arise in connection with the new injectable facility.
Management Outlook: FY27 a Building Year, FY28 a Growth Year
The management described FY27 as a year of building, with multiple projects under execution simultaneously.
The company is progressing with:
- Noumed integration
- Australian manufacturing capacity
- New injectable manufacturing facility
- R&D expansion
- Complex injectable development
- Potential US market entry
Management expects the benefits of these initiatives to become more visible from FY28, when the new assets are expected to contribute more meaningfully to revenue, earnings and cash flows.
Key Takeaways for Investors
Sai Parenterals’ Q1 FY27 earnings call highlighted a business undergoing significant transformation. Standalone operations delivered strong growth, while consolidated margins improved sequentially despite supply-chain disruptions affecting the Australian business.
The proposed ₹101.85 crore redeployment of IPO funds, 60% investment in Saicriti Pharma, acquisition of Prathyak Laboratories and expansion of Noumed’s Australian operations could significantly increase the company’s manufacturing and R&D capabilities.
The company’s ₹750 crore FY27 revenue target and approximately 17% EBITDA margin guidance remain unchanged.
The key factors to watch in the coming quarters will be the execution of the new injectable facility, completion of the R&D acquisition, ramp-up of the Australian facility, realization of the renewed EBOS contract, and the company’s ability to translate its expanded capacity into sustainable revenue and cash-flow growth.
This article is based on the company’s Q1 FY27 earnings conference call transcript dated August 12, 2026. Forward-looking statements represent management’s expectations and are subject to business, regulatory, market, and execution risks. This is for informational purposes only and should not be considered investment advice.